Clearstate Pte. Ltd.
and
United BioSource Corporation (UBC)
announced a strategic partnership to provide global market access, pricing, and reimbursement strategies for manufacturers of biopharmaceuticals, medical devices, and other medical technology.
The agreement reinforces Clearstate’s position as a source for accurate and actionable market intelligence across the Asia-Pacific region and builds upon UBC’s leadership in delivering global market access strategies for life science products. The alliance provides UBC and its clients with access to the high quality market access, pricing, and reimbursement information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.